Clinical Trial: Quetiapine in Specific Phobia
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Anxiolytic Effects of Single-dose Quetiapine XR Administration on Clinical Symptoms and Amygdala Activation During Exposure in Patients With Simple Phobia
Brief Summary: The study hypothesis is that quetiapine XR has anxiolytic properties. The study aims to investigate the putative anxiolytic properties of quetiapine XR in patients with anxiety disorders. Therefore, in a proof-of-concept design patients with simple phobia will be selected to investigate specific anxiolytic and antipanic activity during acute anxiety. Moreover, in a combined fMRI/visual stimulus presentation paradigm activity of fear-network associated brain structures such as the amygdala will be investigated under treatment with quetiapine XR or placebo. Additionally, genetic factors potentially mediating anxiolytic properties of quetiapine will be studied.
Detailed Summary:
Sponsor: University Hospital Muenster
Current Primary Outcome: VAS-Anxiety [ Time Frame: on study day ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- State-Trait-Anxiety-Inventory (STAI) [ Time Frame: on study day ]
- Beck Anxiety Inventory (BAI) [ Time Frame: on study day ]
- Phobia specific questionnaire [ Time Frame: on study day ]
- Acute Panic Inventory (API) [ Time Frame: on study day ]
- Profile of Mood States (POMS) [ Time Frame: on study day ]
- VAS-Avoidance [ Time Frame: on study day ]
- VAS-Tension [ Time Frame: on study day ]
- VAS-Sedation [ Time Frame: on study day ]
- amygdala reactivity [ Time Frame: on study day ]
Original Secondary Outcome: Same as current
Information By: University Hospital Muenster
Dates:
Date Received: March 30, 2009
Date Started: April 2009
Date Completion:
Last Updated: March 30, 2011
Last Verified: March 2011
